Briefly, the regimen started with three monthly loading doses of anti-VEGF, followed by a monthly observation period, in order to determine the individual injection-recurrence interval. Active recurrence was defined as the presence of any intra-or subretinal fluid (i.e., a no-tolerance regimen) or the presence of new haemorrhage. The observed interval, from the last injection to the first reappearance of disease activity, was then used to calculate the future treatment interval (shortest: half a month; longest: 3 months). This was applied in a treatment plan including several injections (three injections if the interval ≤ 2 months, two injections if the interval ≥ 2.5 months), followed by a monitoring visit at the same time-interval after the injection series. The monitoring visit allowed for periodic adjustment of the treatment interval, depending on the presence or absence of exudative signs on SD-OCT. The patients remained on the same drug during the entire 2-year study period.
